Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
126.7 ^USD	-1.66%		+8.15%	+31.35%

Mar. 21	FDA greenlights Italfarmaco's drug for rare muscular dystrophy	RE
Mar. 12	Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	Mar. 01	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	Feb. 29	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	Feb. 29	MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	Feb. 29	MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $145 From $130, Keeps Buy Rating	Feb. 14	MT
BMO Capital Starts Sarepta Therapeutics With Outperform Rating, $170 Price Target	Jan. 31	MT
RBC Trims Price Target on Sarepta Therapeutics to $151 From $155, Keeps Outperform Rating	Jan. 25	MT
Needham Raises Price Target on Sarepta Therapeutics to $140 From $93, Keeps Buy Rating	Jan. 10	MT
RBC Raises Price Target on Sarepta Therapeutics to $155 From $148, Keeps Outperform Rating	Jan. 03	MT
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Buy Rating, $109 Price Target	Dec. 12	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	Nov. 21	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	Nov. 21	MT
Needham Raises Price Target on Sarepta Therapeutics to $93 From $82, Keeps Buy Rating	Nov. 02	MT
Cantor Fitzgerald Downgrades Sarepta Therapeutics to Neutral From Overweight, Cuts Price Target to $40 From $166	23-10-31	MT
Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $146 From $183, Maintains Overweight Rating	23-10-31	MT
Oppenheimer Downgrades Sarepta Therapeutics to Perform From Outperform	23-10-31	MT
Needham Adjusts Sarepta Therapeutics Price Target to $82 From $185, Maintains Buy Rating	23-10-31	MT
RBC Cuts Price Target on Sarepta Therapeutics to $148 From $217, Keeps Outperform Rating	23-10-31	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $174 From $173, Maintains Buy Rating	23-08-04	MT
RBC Lifts Price Target on Sarepta Therapeutics to $223 From $221, Keeps Outperform Rating	23-08-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Analyst Reco.

Filters